Innovative clinical trials that enhance the understanding of cardiovascular disease and improve the care of patients.

Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.

LEARN MORE

Academic Trial Leadership

TIMI Study Group investigators provide leadership for clinical trial design, execution, and analysis

Global Trial Operations

Global Trial Management, Biostatistics, Clinical Events Committee, Safety Desk, Medical Hotline

Core Labs

Biomarkers, Proteomics, Metabolomics, Genomics, ECG

Publications

Practice-changing contributions to the medical literature

Current Trials

Recent News and Publications

03/14/2015 - OSLER SLIDES AVAILABLE (pdf) MORE

03/14/2015 - New Publication: Sabatine et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events MORE

03/14/2015 - PEGASUS-TIMI 54 SLIDES AVAILABLE (pdf) MORE

03/14/2015 - New Publication: Bonaca et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction MORE

03/05/2015 - TIMI presentations at ACC.15 (pdf) MORE

03/04/2015  - Press Release: Genetic Risk Linked to Clinical Benefit of Statin Therapy MORE

03/03/2015  - New Publication: Mega et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials MORE

01/14/2015 – PEGASUS-TIMI 54 meets its primary endpoint. MORE

01/09/2015 Edoxaban (Savaysa) studied in ENGAGE AF-TIMI 48 is approved by FDA. MORE